82% of SMA children treated pre-symptomatically with Zolgensma achieved developmental motor milestones

18 June 2021
2020_novartis_big

Swiss Pharma giant Novartis (NOVN: VX) has announced positive new data about Zolgensma (onasemnogene abeparvovec), an essential, one-time treatment and the only gene therapy for spinal muscular atrophy (SMA), from two clinical trials including the completed two-copy cohort of the Phase III SPR1NT clinical trial that demonstrates age-appropriate development when used pre-symptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline, as well as and the completed Phase III STR1VE-EU trial which demonstrated rapid improvements in motor function following treatment with Zolgensma.

Highlights of the trials’ results

The data will be presented at the European Academy for Neurology (EAN) Virtual Congress 2021 (June 19–22), but the main findings are as follows:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology